• Explore /
  • Poster
  • / FOLFOX versus POF (Paclitaxel plus FOLFOX) versus IP PAC (Intraperitoneal Paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.

FOLFOX versus POF (Paclitaxel plus FOLFOX) versus IP PAC (Intraperitoneal Paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.

Abstract Poster

Authors

null

Rongbo Lin

Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China

Rongbo Lin , Hui Li , Yigui Chen , Jinfeng Zhu , Peicheng Lin , Wujin Chen , Wenzheng Fang , Jie Liu , Shen Zhao , Nanfeng Fan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02845908

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 6)

DOI

10.1200/JCO.2019.37.4_suppl.6

Abstract #

6

Poster Bd #

D16

Abstract Disclosures

Similar Posters

First Author: Shen Zhao

First Author: Rongbo Lin

First Author: Rongbo Lin

First Author: Kirstin Breithaupt